Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The STELLAR Trial
NCT07317934Phase 3Recruiting
- Sponsor
- Innostellar Biotherapeutics
- Start
- Jan 2026
- Primary completion
- Mar 2028
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 3 trial of LX102 in neovascular age-related macular degeneration (NVAMD), sponsored by Innostellar Biotherapeutics. Started Jan 2026; status: recruiting.
02
Drugs
LX102
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07317934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07317934.